In vivo Electroporation

• The administration of brief electrical pulses creates transient "pores" in the cell membranes, which allow chemotherapy drugs or large molecules such as nucleic acids to enter the cell cytoplasm. In addition, the electrical gradient inside the tissue allows transportation of the transduced molecule inside cell nuclei. Immediately following cessation of the electrical field, the pores seal.
  
  
• EVVIVAX Scientists have a long standing experience with this technology.

Clinical Trials

To meet the need for safer and more effective treatments for canine cancer, EVVIVAX is conducting clinical trials in collaboration with the University of Pisa, Italy and VOS (Veterinary Oncology Service), New York, USA:

Tel-eVax

AAHSD000080 
Evaluating a targeted Telomerase vaccine to stimulate anti-tumor immunity and prolong survival times in dogs and cats with various cancers – Species: Canine and Feline

Erb-eVax

AAHSD000081 
Evaluating a targeted her2/neu cancer vaccine for the stimulation of anti-tumor immunity and prolonging survival times in dogs with osteosarcoma (bone cancer) – Species: Canine

AAHSD000082
Evaluating a targeted her2/neu cancer vaccine for the stimulation of anti-tumor immunity and prolonging survival times in dogs with mammary adenocarcinoma (bone cancer) – Species: Feline

AAHSD000085 
Evaluating a targeted her2/neu cancer vaccine for the stimulation of anti-tumor immunity and prolonging survival times in dogs with transitional cell carcinoma (bladder or prostate cancer). Species: Canine

Details are available at AVMA Animal Health Studies Database (AAHSD).

Additional trials for other cancer types are in development

Our Vision

Evvivax

Engineered Veterinary Vectored Immunotherapy and Vaccines

Via Castel Romano, 100 - Rome 00128 - Italy
VAT IT 13919361009

http://www.evvivax.com

This email address is being protected from spambots. You need JavaScript enabled to view it.

Engineered Veterinary Vectored Immunotherapy and Vaccines: EVVIVAX

EVVIVAX is a spin-off of Takis Biotech, a company developing a number of Innovative Immunotherapies

EVVIVAX is at the forefront of nucleic-acid based therapies, process development, industrial scale production and clinical trial execution

EVVIVAX stems from new, European platform technologies, aims to offer novel therapeutic avenues to pet cancer patients, with the strong translational potential to complement current human Immune-Oncology approaches in the next future.